Evidence map›Paper›PMID 33203693›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Case-Control Studies.

Jian-Min Yuan, Yue Wang, Renwei Wang, Hung N Luu, Jennifer Adams-Haduch, Woon-Puay Koh, Yu-Tang Gao, Jaideep Behari, Michael T Lotze

Open access · hybridAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  2. Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.Journal of immunotherapy and precision oncology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Jian-Min YuanUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. yuanj@upmc.edu.ORCID 0000-0002-4620-3108
Yue WangUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Renwei WangUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Hung N LuuUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-2172-1849
Jennifer Adams-HaduchUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Woon-Puay KohHealth Service and Systems Research, Duke-NUS Medical School, Singapore.ORCID 0000-0002-5674-6341
Yu-Tang GaoDepartment of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jaideep BehariDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania.
Michael T LotzeUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-3988-5419
University of Pittsburgh · USUPMC Hillman Cancer Center · USNational University of Singapore · SGRenji Hospital · CN

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
Novel Determinants for Progression of Non-Alcoholic Fatty Liver Disease to Hepatocellular Carcinoma and Other Health OutcomesR01CA255809 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BEHARI, JAIDEEP, YUAN, JIAN-MIN · 2021 to 2025
$3.7M
The Singapore Chinese Health StudyU01CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2019 to 2019
$150k
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA144034NCI NIH HHS R01 CA255809NCI NIH HHS U01 CA182876NCI NIH HHS UM1 CA182876
6 · The paper itself

Abstract

backgroundIL27 mRNA is highly enriched in the tissue of hepatocellular carcinoma. Overexpression of IL27 gene has been found to increase T-cell expression of inhibitory receptors, an immunosuppressive feature in tumor microenvironment, that promotes the development of hepatocellular carcinoma.

methodsTwo parallel case-control studies of hepatocellular carcinoma, each with 100 case-control pairs were conducted in the Singapore Chinese Health Study and the Shanghai Cohort Study to examine the association between serum IL27 levels and risk of developing hepatocellular carcinoma.

resultsThe IL27 concentrations were significantly elevated in sera collected from study participants 4 to 5 years prior to the diagnosis of hepatocellular carcinoma in both cohort studies. Compared with the lowest tertile of IL27, odds ratios (OR) of hepatocellular carcinoma for the highest tertile of IL27 was 46.08 [95% confidence interval (CI), 4.68-453.86] in the Singapore Chinese Health Study and 19.09 (95% CI, 3.81-95.57) in the Shanghai Cohort Study (both

conclusionsLevels of IL27 in prediagnostic sera were significantly associated with increased risk of hepatocellular carcinoma development. IMPACT: IL27, through its immunosuppressive property, may play a significant role in the development of hepatocellular carcinoma. Serum levels of IL27 may be used as a biomarker for prediction of hepatocellular carcinoma development.

Indexed as

AgedBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesFemaleHumansInterleukin-27Liver NeoplasmsMaleMiddle AgedPredictive Value of TestsRisk AssessmentRisk FactorsSingaporeBiomarkers, TumorInterleukin-27

Identifiers

PMID33203693
PMCPMC7867592
OpenAlexW3101003344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.